Rhngf 180 µg/ml eye drops solution (DrugBank: rhNGF)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 90 | Retinitis pigmentosa | 2 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02609165 (ClinicalTrials.gov) | May 2015 | 12/10/2015 | Nerve Growth Factor Eye Drops Treatment in Patients With Retinitis Pigmentosa and Cystoid Macular Edema | Nerve Growth Factor Eye Drops as a Novel Treatment for Vision Loss in Patients With Retinitis Pigmentosa: From Preclinical to Clinical Phase II Trial | Retinitis Pigmentosa;Cystoid Macular Edema | Drug: rhNGF 180 µg/ml eye drops solution;Drug: vehicle eye drops | Ospedale San Raffaele | Dompé Farmaceutici S.p.A | Completed | 18 Years | N/A | All | 45 | Phase 2 | Italy |
| 2 | NCT02110225 (ClinicalTrials.gov) | January 2014 | 8/4/2014 | A Dose Ranging Study to Evaluate the Safety and Potential Efficacy of rhNGF in Patients With Retinitis Pigmentosa (RP) | A 24 Week Phase Ib/II, Multicenter, Randomized, Controlled, Parallel Group, Dose Ranging Study With a 24 Week Follow-up to Evaluate Safety and Potential Efficacy of 2 Doses (60, 180 µg/ml) of rhNGF Solution vs Vehicle in Patients With RP. | Retinitis Pigmentosa | Drug: rhNGF 60 µg/ml eye drops solution;Drug: rhNGF 180 µg/ml eye drops solution;Drug: Placebo | Dompé Farmaceutici S.p.A | NULL | Completed | 18 Years | N/A | All | 50 | Phase 1;Phase 2 | Italy |